Compare Genuine Parts Company (GPC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Neurocrine Biosciences Inc — how do they compare? Genuine Parts Company trades at $125.39 (market cap $16.65B), while Neurocrine Biosciences Inc trades at $172.51 (market cap $17.30B). The key difference: Genuine Parts Company and Neurocrine Biosciences Inc are close in size by market cap, and Genuine Parts Company pays a 3.51% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| GPC | NBIX | |
|---|---|---|
Market Cap | $16.65B | $17.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $180.55 |
52-Week Low | $92.47 | $123.10 |
Enterprise Value | $22.87B | $16.39B |
Dividend Yield | 3.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.40, up 2.65% with a bullish technical signal. The stock shows mixed fundamentals with a high P/E ratio of 275 but strong gross margins of 36.87%. Recent earnings beat expectations in Q1 2026 after two consecutive misses, with Q2 2026 results expected July 21. Analyst consensus is mixed with 43% buy ratings and a $133 price target, while technical indicators show support at $119-120 and resistance at $122-124.
GPC presents a cautious opportunity with dividend stability but faces profitability challenges. The 70-year dividend growth history provides income appeal, though net margins below 1% and declining cash flow trends warrant monitoring. Upside exists if Q2 earnings beat expectations, but weak profitability and rising debt-to-asset ratios pose significant risks to shareholder value.
Neurocrine Biosciences (NBIX) trades at $172.14, up 0.09% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 98.17% gross margins and 21.55% net income margin, supported by revenue growth from $2.86B to $3.1B projected. Recent news highlights pipeline advancements including Phase 2 studies and positive clinical data presentations at ENDO 2026.
NBIX presents compelling investment potential with 86% analyst buy ratings and $195.75 consensus target, offering 14% upside. Key catalysts include Q2 earnings on July 30 and continued pipeline execution. Risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's valuation at 26.47 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
